ASCO GU 2018 Prostate Cancer

Viewing 1-20 of 88 articles

ASCO GU 2018: Phase II Trial of 6 Months ADT/Abiraterone Acetate Plus Prednisone and Definitive Radiotherapy - Intermediate to High Risk Localized Prostate Cancer - AbiRT Trial

ASCO GU 2018: Expression of Immune Checkpoints on Circulating Tumor Cells in Men with Metastatic Prostate Cancer

ASCO GU 2018: Clinical Utility of Foundation One Tissue Molecular Profiling in Men with Metastatic Prostate Cancer

ASCO GU 2018: Patterns of Progression in Bone and Soft Tissue Following Treatment with Ra-223 in Metastatic Castrate Resistant Prostate Cancer

ASCO GU 2018: Retrospective Analysis of Fatigue in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide

ASCO GU 2018: Abiraterone or Docetaxel in Men with Metastatic Castration-sensitive Prostate Cancer: A Pooled Analysis of Castration Resistance-free Survival and Toxicity

ASCO GU 2018: Real-world Study of Enzalutamide and Abiraterone Acetate (with Prednisone) Tolerability (REAAcT): Results

ASCO GU 2018: Survival Outcomes of Pre-Metastatic Castration-Resistant Prostate Cancer and the Burden of Developing Metastasis: A Systematic Literature Review

ASCO GU 2018: An Observational Study Profiling Biospecimens from 10,000 Metastatic Prostate Cancer Patients to Screen for Molecular Alterations

ASCO GU 2018: Real-World Experience with Docetaxel for Castration-Sensitive Prostate Cancer from a Population-Based Analysis

ASCO GU 2018: Best of Journals: Prostate Cancer - Medical Oncology

ASCO GU 2018: Interim analysis of a prospective randomized trial of dietary carbohydrate restriction for men with a rising PSA after failed primary treatment: Carbohydrate and Prostate Study 2

ASCO GU 2018: A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer

ASCO GU 2018: Comparative Assessment of Abiraterone or Enzalutamide Activity in the PROREPAIR-B Study

ASCO GU 2018: Influence of CHAARTED, STAMPEDE, and LATITUDE eligibility criteria on utilization of abiraterone and docetaxel

ASCO GU 2018: A Phase 2 Study of Olaparib and Durvalumab in mCRPC in an Unselected Population

ASCO GU 2018: Blood-brain barrier penetration of darolutamide compared with enzalutamide using whole body autoradiography

ASCO GU 2018: Best of Journals: Prostate - Surgery

ASCO GU 2018: Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE)

ASCO GU 2018: Ability of multiparametric MRI to predict prostate tumor heterogeneity on targeted biopsy

1
2
3
4
5

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.